
Addressing KRAS Resistance, RAS(ON) Therapies Find Limelight at AACR
Successfully targeting KRASG12C has been one of the major achievements of the decade in cancer care. Starting in 2021, almost 40 years after discovery of the KRAS gene, FDA granted accelerated approvals of sotorasib (Lumakras, Amgen) and adagrasib (Krazati …